Search Results - "Agha, I."

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives by Gauthier, J., Yakoub-Agha, I.

“…Progress in our understanding of basic immunology along with the advent of bioengineering technologies have made possible the production of human T-cells…”
Get full text

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation by Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Dignan, F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Okamoto, S, Pagliuca, A, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, Duarte, R F, Carreras, E

“…Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after…”
Get full text

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) by Hayden, P.J., Roddie, C., Bader, P., Basak, G.W., Bonig, H., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., Sanchez-Guijo, F., Jäger, U., Hildebrandt, M., Hudecek, M., Kersten, M.J., Köhl, U., Kuball, J., Mielke, S., Mohty, M., Murray, J., Nagler, A., Rees, J., Rioufol, C., Saccardi, R., Snowden, J.A., Styczynski, J., Subklewe, M., Thieblemont, C., Topp, M., Ispizua, Á.U., Chen, D., Vrhovac, R., Gribben, J.G., Kröger, N., Einsele, H., Yakoub-Agha, I.

“…Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for…”
Get full text

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry by Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., Harel, S., Perrot, A., Bories, P., Vincent, L., Lamure, S., Mohty, M., Malard, F., Manier, S., Yakoub‐Agha, I., Schiano De Colella, J.‐M., Brisou, G., Talbot, A., Decaux, O., Houot, R., Le Gouill, S., Bigot, N., Facon, T., Corre, J., Moreau, P., Arnulf, B.

“…Summary Idecabtagene vicleucel (ide‐cel), a chimeric antigen receptor T‐cell therapy targeting B‐cell maturation antigen (BCMA), received early access program…”
Get full text

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) by Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Duarte, R F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Pagluica, T, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, Carreras, E

“…Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a potentially life-threatening complication of hematopoietic SCT (HSCT). This review…”
Get full text

Artificial neural network discovery of a switchable metasurface reflector by Thompson, J. R., Burrow, J. A., Shah, P. J., Slagle, J., Harper, E. S., Van Rynbach, A., Agha, I., Mills, M. S.

“…Optical materials engineered to dynamically and selectively manipulate electromagnetic waves are essential to the future of modern optical systems. In this…”
Get full text

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study by Ludwig, H, Weisel, K, Petrucci, M T, Leleu, X, Cafro, A M, Garderet, L, Leitgeb, C, Foa, R, Greil, R, Yakoub-Agha, I, Zboralski, D, Vauléon, S, Dümmler, T, Beyer, D, Kruschinski, A, Riecke, K, Baumann, M, Engelhardt, M

Get full text

An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT by Hayden, P.J., Sirait, T., Koster, L., Snowden, J.A., Yakoub-Agha, I.

“…Two chimeric antigen receptor (CAR) T-cell therapies - Tisagenlecleucel (Kymriah™) and Axicabtagene ciloleucel (Yescarta™) - have been approved for commercial…”
Get full text

Better early outcome with enteral rather than parenteral nutrition in children undergoing MAC allo-SCT by Gonzales, F., Bruno, B., Alarcón Fuentes, M., De Berranger, E., Guimber, D., Behal, H., Gandemer, V., Spiegel, A., Sirvent, A., Yakoub-Agha, I., Nelken, B., Duhamel, A., Seguy, D.

“…There is no consensus on the type of nutritional support to introduce in children undergoing allogeneic stem cell transplantation (allo-SCT) after…”
Get full text

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT by Spyridonidis, A, Labopin, M, Schmid, C, Volin, L, Yakoub-Agha, I, Stadler, M, Milpied, N, Socie, G, Browne, P, Lenhoff, S, Sanz, M A, Aljurf, M, Mohty, M, Rocha, V

“…To describe outcomes, treatment and prognostic factors that influence survival of adult patients with acute lymphoblastic leukemia (ALL), who relapsed after…”
Get full text

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis by McLornan, D., Eikema, D. J., Czerw, T., Kröger, N., Koster, L., Reinhardt, Hans Christian, Angelucci, E., Robin, M., Bornhäuser, M., Passweg, J., Clark, A., Vydra, J., Blau, I. E., Niittyvuopio, R., Platzbecker, U., Cornelissen, J. J., Chevallier, P., Srour, M., Stamatovic, D., Martinez-Lopez, J., de Wreede, L., Hayden, P., Hernández-Boluda, J. C., Yakoub-Agha, I.

“…We performed a retrospective assessment of patient- and transplant-specific characteristics and outcomes for 4142 patients undergoing allogeneic haematopoietic…”
Get full text

Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry by Sadowska-Klasa, A., Zaucha, J. M., Labopin, M., Bourhis, J. H., Blaise, D., Yakoub-Agha, I., Salmenniemi, U., Passweg, J., Fegueux, N., Schroeder, T., Giebel, S., Brissot, E., Ciceri, F., Mohty, M.

“…Secondary acute lymphoblastic leukemia (s-ALL) comprises up to 10% of ALL patients. However, data regarding s-ALL outcomes is limited. To answer what is the…”
Get full text

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents by Mohty, B, El-Cheikh, J, Yakoub-Agha, I, Avet-Loiseau, H, Moreau, P, Mohty, M

“…Treatment of multiple myeloma has evolved over the last decade, most notably with the introduction of highly effective novel agents. It is now possible to aim…”
Get full text

Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT by Cahu, X, Labopin, M, Giebel, S, Aljurf, M, Kyrcz-Krzemien, S, Socié, G, Eder, M, Bonifazi, F, Bunjes, D, Vigouroux, S, Michallet, M, Stelljes, M, Zuckerman, T, Finke, J, Passweg, J, Yakoub-Agha, I, Niederwieser, D, Sucak, G, Sengeløv, H, Polge, E, Nagler, A, Esteve, J, Mohty, M

“…Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option for adult patients with T-cell ALL (T-ALL). Meanwhile, few allo-SCT data…”
Get full text

Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT by Ruggeri, A, Sanz, G, Bittencourt, H, Sanz, J, Rambaldi, A, Volt, F, Yakoub-Agha, I, Ribera, J M, Mannone, L, Sierra, J, Mohty, M, Solano, C, Nabhan, S, Arcese, W, Gluckman, E, Labopin, M, Rocha, V

“…We report outcomes after single (s) and double (d) umbilical cord blood transplantation (UCBT) after myeloablative conditioning (MAC) regimen for 239 patients…”
Get full text

Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies by Pascal, L, Mohty, M, Ruggeri, A, Tucunduva, L, Milpied, N, Chevallier, P, Tabrizi, R, Labalette, M, Gluckman, E, Labopin, M, Yakoub-Agha, I

“…This study aimed to assess the impact of antithymocyte globulin (ATG) on patient outcome in a retrospective series of 91 patients (median age: 12 years) who…”
Get full text

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT by Sellner, L, Boumendil, A, Finel, H, Choquet, S, de Rosa, G, Falzetti, F, Scime, R, Kobbe, G, Ferrara, F, Delmer, A, Sayer, H, Amorim, S, Bouabdallah, R, Finke, J, Salles, G, Yakoub-Agha, I, Faber, E, Nicolas-Virelizier, E, Facchini, L, Vallisa, D, Zuffa, E, Sureda, A, Dreger, P

“…Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is…”
Get full text

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT by Potter, V., Gras, L., Koster, L., Kroger, N., Sockel, K., Ganser, A., Finke, J., Labussiere-Wallet, H., Peffault de Latour, R., Koc, Y., Salmenniemi, U., Smidstrup Friis, L., Jindra, P., Schroeder, T., Tischer, J., Arat, M., Pascual Cascon, M., de Wreede, L. C., Hayden, P., Raj, K., Drozd-Sokolowska, J., Scheid, C., McLornan, D. P., Robin, M., Yakoub-Agha, I.

“…The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to…”
Get full text

Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC by Magro, L, Gauthier, J, Richet, M, Robin, M, Nguyen, S, Suarez, F, Dalle, J-H, Fagot, T, Huynh, A, Rubio, M-T, Oumadely, R, Vigouroux, S, Milpied, N, Delcampe, A, Yakoub-Agha, I

“…Chronic GvHD-related keratoconjunctivitis sicca (cGvHD-related KCS) can significantly alter the quality of life of patients after allogeneic hematopoietic stem…”
Get full text

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone by Avet-Loiseau, H, Soulier, J, Fermand, J-P, Yakoub-Agha, I, Attal, M, Hulin, C, Garderet, L, Belhadj, K, Dorvaux, V, Minvielle, S, Moreau, P

“…This retrospective analysis investigated the prognostic value of del(13) and t(4;14) abnormalities and the impact of prior treatment on outcomes in 207 heavily…”
Get full text